Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 41.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,999 shares of the company’s stock after acquiring an additional 6,175 shares during the quarter. SG Americas Securities LLC’s holdings in Zevra Therapeutics were worth $138,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZVRA. VisionPoint Advisory Group LLC acquired a new stake in Zevra Therapeutics during the third quarter worth $33,000. California State Teachers Retirement System purchased a new position in shares of Zevra Therapeutics during the third quarter worth $36,000. Strs Ohio purchased a new position in shares of Zevra Therapeutics during the third quarter worth $37,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Zevra Therapeutics during the third quarter worth $48,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Zevra Therapeutics during the third quarter worth $52,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. William Blair restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Maxim Group lifted their target price on Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $19.50.

Zevra Therapeutics Stock Down 0.3 %

ZVRA opened at $4.77 on Wednesday. The business’s 50-day simple moving average is $5.96 and its 200-day simple moving average is $5.37. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.18 and a current ratio of 1.18. Zevra Therapeutics, Inc. has a one year low of $3.89 and a one year high of $7.28. The stock has a market capitalization of $207.16 million, a P/E ratio of -3.70 and a beta of 1.81.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.